Chandan Healthcare Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹576 Cr
- P/E
- 21.92
- ROE
- 19.84%
- PEG
- 0.21
- Price to sales
- 1.99
- Debt to equity
- 0.31
- 52W high / low
- ₹347 / ₹191
- EBITDA margin
- 19.72%
- Net profit margin
- 11.12%
- Promoter holding
- 47.20%
- Sales (last year)
- ₹289 Cr
Guidance scorecard · Q1 FY27 call
What Chandan Healthcare Ltd's management guided
and where it ranks in Healthcare Services
Healthcare Services
RevenueQ1 FY27 call
40%+- The company expects more than 50% year-on-year top-line growth for the next three years, focusing solely on the diagnostics business after divesting the pharmacy segment.
- Expansion from 3 to 15 states supports this growth, with several centers and labs under construction, expected to be operational within months.
- Franchise business is a key growth driver, targeting over 1,000 franchises this year and aiming for 3,000 in three years, potentially achieving the target earlier.
2 more points from Chandan Healthcare Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Chandan Healthcare Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Major part of the current year's capex has already been invested, including acquisition of one center in April and ongoing construction of comprehensive diagnostic centers and labs.
- Plans to open eight comprehensive centers and more than five to six labs, along with two PET scans and one genome lab, to be completed before December 2026.
- Total additional capex expected of around INR 10 crores+, to be funded from internal accruals or debt if needed.
- No capital investment required for franchise model; franchisees invest their own capital (~INR 1 lakh) for computer and equipment, paying initial franchise fee (INR 25,000 to 1 lakh) to the company.
2 more points from Chandan Healthcare Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
PlannedSee what Chandan Healthcare Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
RisingAsk what Chandan Healthcare Ltd said on the order book →
Full Q1 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- 2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹903 Cr | — | |
| 2 | Chandan HealthcaThis stock | 40%+ | Flat | ₹583 Cr | 22.2 |
| 3 | Aster DM Quality Care Ltd | 20–40% | Up 2%+ | ₹58,782 Cr | 162.9 |
| 4 | 20–40% | Up 0–2% | ₹1,730 Cr | 17.5 | |
| 5 | 20–40% | Up 0–2% | ₹580 Cr | 11.9 | |
| 6 | 20–40% | Flat | ₹1.13L Cr | 53.9 |
Sign up free to see every company in the sector ranking and track Chandan Healthcare Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingChandan Healthcare Ltd announcements
All announcements →- Acquisition / mergerNotableChandan Healthcare Limited acquires Ansh Diagnostics & Health Care units in Ghaziabad
Financials of Chandan Healthcare Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Chandan Healthcare Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Dec 2024 | Sep 2025 | Dec 2025 | |
|---|---|---|---|
| Sales + | 54.64 | 67.90 | 65.01 |
| Expenses + | 45.75 | 53.75 | 53.17 |
| Operating Profit | 8.89 | 14.15 | 11.84 |
| OPM % | 16.27% | 20.84% | 18.21% |
| Other Income + | 0.17 | 0.84 | -1.46 |
| Interest | 1.09 | 1.40 | 1.28 |
| Depreciation | 1.35 | 2.46 | 2.40 |
| Profit before tax | 6.62 | 11.13 | 6.70 |
| Tax % | 30.21% | 25.79% | 24.93% |
| Net Profit + | 4.20 | 7.80 | 4.54 |
| EPS in Rs | 2.10 | 3.19 | 1.86 |
Financials of Chandan Healthcare Ltd
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Sales + | 120 | 137 | 177 | 230 |
| Expenses + | 117 | 128 | 150 | 189 |
| Operating Profit | 2 | 9 | 26 | 41 |
| OPM % | 2% | 7% | 15% | 18% |
| Other Income + | 0 | 0 | 1 | 2 |
| Interest | 2 | 2 | 3 | 5 |
| Depreciation | 2 | 2 | 3 | 7 |
| Profit before tax | -1 | 5 | 21 | 32 |
| Tax % | 3% | 28% | 24% | 27% |
| Net Profit + | -1 | 3 | 16 | 24 |
| EPS in Rs | -0.56 | 1.68 | 8.14 | 9.07 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of Chandan Healthcare Ltd
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 20 | 24 | 24 |
| Reserves | 4 | 7 | 21 | 98 | 114 |
| Borrowings + | 17 | 21 | 36 | 48 | 67 |
| Other Liabilities + | 41 | 49 | 41 | 40 | 68 |
| Total Liabilities | 82 | 98 | 118 | 211 | 273 |
| Fixed Assets + | 29 | 33 | 48 | 76 | 91 |
| CWIP | 0 | 0 | 0 | 4 | 5 |
| Investments | 6 | 7 | 3 | 1 | 47 |
| Other Assets + | 46 | 58 | 66 | 129 | 130 |
| Total Assets | 82 | 98 | 118 | 211 | 273 |
Financials of Chandan Healthcare Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 6 | 4 | 1 | -29 |
| Cash from Investing Activity + | -11 | -6 | -15 | -36 |
| Cash from Financing Activity + | 3 | 2 | 16 | 67 |
| Net Cash Flow | -1 | 0 | 2 | 2 |
| Free Cash Flow | -1 | -1 | -18 | -68 |
| CFO/OP | 275% | 60% | 23% | -50% |
Financials of Chandan Healthcare Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 88 | 63 | 59 | 74 |
| Inventory Days | 46 | 71 | 96 | 126 |
| Days Payable | 185 | 251 | 102 | 102 |
| Cash Conversion Cycle | -51 | -117 | 53 | 98 |
| Working Capital Days | -11 | -21 | -1 | 75 |
| ROCE % | 16% | 37% | 29% |
Guidance history
How Chandan Healthcare Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 40%+ | Flat | Planned | Planned | Rising |
| Q4 FY26 call → | 20–40% | Up 2%+ | Planned | Planned | — |
| Q3 FY26 call → | 40%+ | Up 2%+ | Planned | Planned | Rising |
| Q2 FY26 call → | 20–40% | Up 2%+ | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
20 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −30.7% | 23% |
| Last 6 months | −6.6% | 45% |
| Last 3 months | −1.7% | 64% |
The price is 32.3% below its all-time high of ₹347.2 (19 Nov 2025). Stocks more than 20% below their peak have their score halved, so 40 became 20.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Chandan Healthcare Ltd: 0.4 × 23 + 0.4 × 45 + 0.2 × 64 = 40, halved to 20 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Chandan Healthcare Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Rainbow Childrens Medicare Ltd (Q2 FY27)
Year-on-year (YoY) growth in revenue: 23.2% . Key investor presentation takeaways from Rainbow Childrens Medicare Ltd's Q2 FY27 investor presentation — and how
- Narayana Hrudayalaya Ltd (Q2 FY27)
Consolidated operating revenue for Q2 FY27: ₹28,440 Mn, up 73.0% YoY (Page 15, 16). Key investor presentation takeaways from Narayana Hrudayalaya Ltd's Q2 FY27
- Artemis Medicare Services Ltd (Q2 FY27)
Q2 FY27 consolidated revenue from operations: INR 31,104 Lacs, up 13.2% YoY (Page 39, 40, 20). Key investor presentation takeaways from Artemis Medicare Service
- Max Healthcare Institute Ltd (Q2 FY27)
Q2 FY27 Gross Revenue: ₹3,219 Cr, up 20% YoY (Page 4, 17) . Key investor presentation takeaways from Max Healthcare Institute Ltd's Q2 FY27 investor presentatio